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ABSTRACT
Human DNA topoisomerase I not only has DNA relaxing
activity, but also splicing factors phosphorylating
activity. Topo I shows strong preference for ATP as the
phosphate donor. We used photoaffinity labeling with
the ATP analogue [α-32P] 8-azidoadenosine-5′-triphos-
phate combined with limited proteolysis to characterize
Topo I domains involved in ATP binding. The majority
of incorporated analogue was associated with two
fragments derived from N-terminal and C-terminal
regions of Topo I, respectively. However, mutational
analysis showed that deletion of the first 138 N-terminal
residues, known to be dispensable for topoisomerase
activity, did not change the binding of ATP or the kinase
activity. In contrast, deletion of 162 residues from the
C-terminal domain was deleterious for ATP binding,
kinase and topoisomerase activities. Furthermore, a
C-terminal tyrosine 723 mutant lacking topoisomerase
activity is still able to bind ATP and to phosphorylate
SF2/ASF, suggesting that the two functions of Topo I
can be separated. These findings argue in favor of the
fact that Topo I is a complex enzyme with a number of
potential intra-cellular functions.
INTRODUCTION
Eukaryotic DNA topoisomerase I changes the linking number of
DNA in individual steps, resulting in the release of a positive or
negative superhelical tension of a topologically fixed DNA
molecule (1). These biochemical properties suggest that this
enzyme may participate in all functional aspects of DNA
including transcription, replication and recombination (2). However,
yeast cells carrying mutations in the gene encoding the major
topoisomerase I activity are viable but grow at slower rate than
wild type cells (3,4). Because the topoisomerase I gene could
complement other mutations in yeast, it was proposed that other
proteins provide overlapping functions which prevent the lethality
of a top1 null mutant (5,6). In contrast, the DNA topoisomerase
I gene is required for complete embryonic development in
Drosophila and mouse (7,8).
Lack of complete understanding of the mechanism underlying
the lethal phenotype caused by DNA topoisomerase I inactivation
in Drosophila and mouse necessitate a better characterisation of
its function in muticellular organisms. The discovery that DNA
topoisomerase I has an intrinsic protein kinase activity (9,10), that
we termed topo I/kinase, led us to propose that this activity may
be required to achieve specific phosphorylation of proteins that
associate either directly or indirectly with the transcription machin-
ery. We now know that topo I/kinase phosphorylates members of the
SR protein family that are associated with actively transcribed
regions of Drosophila polytene chromosomes (11). Since SR
proteins are involved in the splice site choice of sequentially
regulated genes in Drosophila (12–14), variations in the phospho-
rylation state of these splicing factors may be instrumental in
regulating Drosophila development. The finding that reversible
phosphorylation can modulate the activity of splicing factors during
RNA splicing (15–20) is consistent with this possibility. In addition,
SR proteins extracted from HeLa cells treated with DNA topoi-
somerase I inhibitors have a different pattern of phosphorylation as
compared with those extracted from untreated cells (9). However,
other protein kinase(s) not affected by the Topo I inhibitors are also
active in vivo but have a different specificity from that of topo I/
kinase (Labourier et al., accompanying paper). Among kinases
phosphorylating SR proteins (21,22), SRPK1 and Clk1 were
shown to induce nuclear redistribution of SR proteins (22,23).
Human DNA topoisomerase I is a nuclear phosphoprotein
composed of 765 amino acids with a predicted molecular mass of
91 kDa (24). It shares 40–50% identical amino acid sequences
with other eukaryotic DNA topoisomerases I and as a result can
be divided into four domains based on regions of extensive
homology (25,26). The C-terminal domain, which contains the
active tyrosine at position 723, is the most conserved domain that
spans from residues 697 to 765 (26). This domain is preceded by
a linker region of positively-charged residues that are not
conserved (26). Residues from positions 198 to 651 form the
conserved core domain which is resistant to proteolysis with
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subtilysin (26). The N-terminal domain is highly charged and
contains four putative nuclear localization signals (residues
59–65, 150–156, 174–180 and 192–198) which are conserved in
this apparently divergent region of DNA topoisomerase I (27).
We were interested in identifying amino acid regions which are
essential for topo I/kinase activity. Here we show that the
C-terminal conserved domain contributes to the ATP binding site
and is therefore essential for kinase activity. Since substitution of
the tyrosine residue at the topoisomerase active site by phenylalanine
does not change the kinase activity of topo I/kinase, we conclude that
the mechanism involved in the DNA-catalyzed reaction is different
from the mechanism by which topo I/kinase phosphorylates SR
proteins.
MATERIALS AND METHODS
Expression and purification of recombinant proteins
The wild type and mutant Y723F recombinant topoisomerase I
proteins were produced following infection of monolayer cultures of
Sf 21 cells with the recombinant baculovirus AcMNPV/hTOPI (a
generous gift from A. M. Zhelkovsky, Tufts University, Boston)
or BlueBac (Y/F) virus (a generous gift from J.J. Champoux),
respectively, at a multiplicity of infection of 10.
The virus encoding Topo-80 was constructed by inserting the
Xho–EcoRI fragment of the human Topo I cDNA into transfer
vector (pBlueBacHis2 C) which was co-transfected with linearized
Autographa californica multiple polyhedrosis virus (AcMPV)
into SF9 cells. This construct encodes additional amino acids (six
histidines and the enterokinase cleavage site) before the Pro 139
in the human DNA topoisomerase I cDNA.
To mutate the C-terminal part of human DNA topoisomerase I
into Topo-δC, the polymerase chain reaction (PCR) was used to
amplify a segment of the human Topo I cDNA from positions
1420 to 1804, taking the first nucleotide of the initiating
methionine as position 1. The amplified fragment contained the
unique HindIII site of human Topo I cDNA at the 5′ end and a SalI
site included in the 3′ end oligonucleotide sequence used for the
PCR reaction. The digestion of this fragment with HindIII–SalI
was used to replace a HindIII–SalI fragment from the transfer
vector (pBlueBacHis 2A) containing the entire human Topo I
cDNA previously cloned between BamHI and EcoRI sites. The
entire Topo I sequence inserted in the Topo-δC transfer vector
was sequenced to confirm the proper construction of the initiation
signal and to ensure that no other mutations were present. All the
methods for co-transfecting, isolating and maintaining recombinant
baculovirus clones were performed according to Invitrogen
manufacture protocols.
Recombinant Topo I mutant proteins were produced and
purified following the same procedure as described by Rossi et al.
(9). Briefly, 500 µl of nuclear extract (500 µg proteins) were
centrifuged for 4 min at 17 000 g to remove aggregated proteins.
The supernatant was mixed with an equal volume of 4 M
ammonium sulfate and incubated at 4C for 1 h. Bulk proteins were
pelleted by centrifugation (10 min at 17 000 g) and 248 mg of
ammonium sulfate were added to the supernatant. After 1 h at 4C
the protein precipitate was collected by centrifugation. The pellet
(250 µg proteins) was resuspended in 500 µl of buffer B (50 mM
HEPES pH 7.0, 10 mM MgCl2, 3 mM MnCl2, 50 mM KCl,
0.5 mM DTT), and then incubated for 30 min at 4C with 50 µl
of nickel agarose beads (Qiagen) equilibrated in the same buffer.
After two washes with 300 µl of buffer B, bound recombinant
proteins were eluted with 40 mM imidazole. Protein concentra-
tions were estimated by Coomassie blue staining of fractionated
proteins in SDS gel using Topo I, previously quantitated by
protein composition analysis, as a standard, and was typically
0.3–1 mg/ml at this stage.
SF2/ASF was expressed in TG1 bacterial strain transfected
with plasmid containing ASF-1 cDNA, (a generous gift from J.
Manley, Columbia University, New York). A large amount of
proteins was purified from inclusion bodies using the procedure
described by Ge et al. (28).
Kinase and topoisomerase assays 
The reaction mixtures for protein kinase activity contained 100 ng
of the recombinant protein, 300 ng of the recombinant SF2/ASF
protein substrate in buffer B and 3 µCi [γ-32P]ATP (3000 Ci/mmol)
in 12 µl final volume and were incubated at 30C for 30 min. The
samples were then mixed with 5 µl of (3X) Laemmli loading
buffer and applied to a 10% SDS–polyacrylamide gel (29). The
fractionated phosphoproteins were revealed by autoradiography.
Following inactivation of Topo I by increasing concentrations of
8N3-ATP in a final volume of 10 µl (Fig. 2B), an aliquot
corresponding to 1 µl (∼100 ng of irradiated proteins) was added and
the final concentration of 8N3-ATP in the kinase assays was adjusted
to 10 µM.
To test the DNA relaxation activity of recombinant Topo I mutant
proteins, 20 ng of each protein was incubated in buffer B with
500 ng supercoiled DNA plasmid in a final volume of 10 µl for 30
min at 30C. The DNA was then extracted with phenol–chloroform,
precipitated with ethanol and electrophoresed in a 0.8% agarose gel
in TBE buffer. The DNA topoisomers were revealed by ethidium
bromide staining.
8N3-ATP cross-linking and chymotrypsin digestion of
photolabeled recombinant proteins 
The reaction mix for photochemical cross-linking contained, in a
total volume of 50 µl, 5 µg of recombinant protein, 50 mM Tris
(pH 7.5), 20 mM AMP-α-S and 50 µM 8N3-ATP (unless
otherwise indicated). [α-32P]8N3-ATP was used at a specific
activity of 0.5–1 Ci/mmol. The photochemical cross-linking of
8N3-ATP to recombinant proteins was performed in 1.5 ml
microfuge tubes for 20 min at room temperature in the dark and
then irradiated with a transilluminator UVC-254 placed 3 cm
under the reaction tubes. Although long exposure times (exceeding
5 min) may result in some proteolysis, it was necessary to expose for
5 min to destroy unreacted 8N3-ATP, which was very important
when digesting the photolabeled protein with chymotrypsin. The
8N3-ATP cross-linked topo I/kinase was utilized for kinase
assays (1 µl aliquots diluted 10 times in buffer B), for relaxation
assays (1 µl aliquots diluted 50 times in buffer B), or for
SDS–PAGE (8 µl aliquots), or subjected to limited proteolysis with
chymotrypsin as described below.
Digestion of photolabeled proteins was carried out at 30C by
adding 1 µl of chymotrypsin (4 µg/ml) to 40 µl of the cross-linking
reaction mixtures immediately after the 5 min exposure to UV light.
Aliquots corresponding to 8 µl were withdrawn at intervals and
mixed with 5 µl of 4X Laemmli loading buffer containing 1 mM
PMSF. The polypeptide fragments were then analyzed by SDS–
PAGE on 10–16% gradient gels (34). Protein and proteolytic
fragment concentrations were estimated by Coomassie blue staining
of SDS gel using Topo I, previously quantitated by protein
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composition analysis, as a standard. Distribution of radioactivity,
from radiolabeled samples, was detected by a Molecular Dynamics
imaging analyzer and autoradiography of dried gel. The relative
amount of [α-32P]8N3-ATP cross-linked to each polypeptide was
quantitated by densitometry scanning of the gel using ImageQuant
software version 3.22 and counting gel slices using cerenkov
counting.
Separation of chymotrypsin peptides and microsequencing
For amino acid microsequencing, the 24K and 80K polypeptides
produced at early time of digestion of full length Topo I were
separated by reverse phase chromatography using an Applied
Biosystem model 130A HPLC and a Spherisorb 300A (100 ×
4.6 mm) column. The polypeptides were resolved with a linear
gradient of solvent B (95% acetonitrile) in solvent A (0.1%
trifluoroacetic acid in H20) at a flow rate of 45 min (0–95% B).
Elution was monitored at 220 nm, and fractions corresponding to
the 80K fragment peak were pooled and applied to a C4 Aquapore
(100 × 2 mm) column. The 80K fragment was then eluted with
a linear acetonitrile gradient 40 min (15–55%) and its N-terminal
amino acid sequence was determined by Edman degradation using
Applied Biosystems technology protein sequencer (model 470A).
All the other fragments resulting from chymotrypsin digestions
were separated by electrophoresis on a 10–16% SDS polyacryl-
amide gel and electrotransferred to a ProBlott membrane (Applied
Biosystems) in 10 mM 3-(cyclohexylamino)-1-propane-sulfonic
acid (CAPS), pH 11.0, containing 10% methanol for 1 h.
Membranes were stained with Coomassie brillant blue and the
discrete bands (66, 14K for Topo I; 66, 14K for Topo-80; 60, 31K)
were excised and subjected to microsequence analysis using an
Applied Biosystems Inc. Model 473 protein sequencer. Phenylthio-
hydantoin (PTH) derivatives of the amino acids were separated
and identified by on-line reverse phase HPLC using an RP-18
column (Brownlee Labs, Applied Biosystems).
Titration of ATP binding to recombinant proteins using
tryptophan fluorescence
Fluorescence experiments were performed on a Fluorolog-II
(Jobin Yvon) spectrofluorometer at 25C. Protein samples
(25 nM) were incubated in a buffer containing 50 mM Tris–HCl,
2 mM MgCl2 and 50 mM KCl. The binding of ATP or 8N3-ATP
was monitored by quenching of the intrinsic tryptophan fluorescence
of recombinant proteins at 332 nm, upon excitation at 295 nm.
The decrease in protein fluorescence was fitted to the appropriate
form of the quadratic equation as previously described (30,31).
The best fit was obtained, with the Kd corresponding to each
protein determined. A maximal fluorescence quenching of 26%
for recombinant proteins that bind ATP was observed.
RESULTS
We have shown previously that recombinant human DNA
topoisomerase I overexpressed in insect cells using the baculovirus
system has the same characteristics as the native HeLa enzyme
(9). It binds ATP efficiently and specifically phosphorylates SR
protein splicing factors at short RS domain regions (Labourier et al.,
accompanying paper). In order to ascertain whether this enzyme is
capable of using other ribonucleotides as phosphate donors, we
examined the effect of different nucleotides as competitors in the
kinase reaction. The purified recombinant topo I/kinase was used in
Figure 1. Inhibition of topo I/kinase activity by nucleotides. The kinase
reactions were performed as described (Materials and Methods) with increasing
concentrations of either AMP, ADP, ATP, GTP, UTP or CTP, 1 µM (lanes 2, 6,
10, 14, 18 or 22 respectively); 10 µM (lanes 3, 7, 11, 15, 19 or 23 respectively),
100 µM (lines 4, 8, 12,16, 20 or 24 respectively), 1 mM (lanes 5, 9, 13,17, 21
or 25 respectively). Ctr indicates the control. The position of SF2/ASF is
indicated on the left.
kinase assays containing increasing concentrations of ATP, GTP,
CTP or UTP and kinase activity was detected by its ability to
phosphorylate bacterially expressed recombinant SF2/ASF with
[γ-32P]ATP. Analysis of the phosphorylated products by SDS–
PAGE and densitometric scanning of the autoradiography (Fig. 1)
revealed that under conditions where the concentration of
[γ-32P]ATP was constant, all four triphosphate nucleotides
enhanced 32P incorporation (compare lane 1 and lanes 10, 14, 18
and 22). This indicates that the nucleotides can alter the Km to an
optimal value or may also suggest allosteric interactions or
additional binding sites for these nucleotides. Under the conditions
of this assay, 100 µM cold ATP completely prevent radiolabeling
of SF2/ASF (lane 12), and there was a 50% reduction of maximal
activity at 10 µM ATP (compare lanes 10 and 11). In contrast,
GTP, UTP and CTP when used at concentrations even as high as
100 µM, did not affect the level of phosphorylation of SF2/ASF
(lanes 16, 20 and 24, respectively). These results suggest that at
least in vitro, ATP is the preferred phosphate donor used by topo I/
kinase to phosphorylate SF2/ASF. Consistent with this, in the
absence of ATP the [γ-32P]GTP did not act as a phosphate donor
(data not shown). However, for reasons that we did not
understand, each of the non-radioactive NTPs appeared to behave
differently. For example, CTP stimulated kinase activity at all
concentrations tested and did not inhibit even at 1 µM (lanes 22–25).
GTP and UTP, on the other hand, stimulate differentially at low
concentrations (compare lanes 14, 15 with 18, 19). As expected,
ADP was also inhibitory but at a 10-fold higher concentration
than ATP (lane 9). Because it possesses one less phosphate group,
ADP probably fits the ATP binding site more loosely and therefore
becomes readily exchangeable with ATP once the phosphate transfer
to SF2/ASF has been accomplished. AMP is less effective than ADP
as a competitor for the binding of ATP, i.e, a much higher
concentration was required to inhibit the phosphorylation of
SF2/ASF (compare lanes 5 and 9). By analogy with known NTP
binding proteins, DNA topoisomerase I is expected to have an ATP
binding motif with a phosphate-loop function. 
The photoaffinity probe [α-32P]8-azido-ATP (8N3-ATP) was
used to investigate the binding of ATP to highly purified
recombinant DNA topoisomerase I. Specific labeling of the
binding site requires that the 8N3-ATP binds with a sufficient
affinity and selectivity to the same site(s) as the natural ligands do.
Therefore, the noncovalent binding of the ATP analogue was first
tested. Human DNA topoisomerase I contains a total of 13
tryptophan residues which can be used as selective probes for
monitoring the kinetics of enzyme–substrate interactions. Addition
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Figure 2. Dissociation constants determination for ATP and 8N3-ATP binding
to recombinant human DNA topoisomerase I (A). Inactivation of kinase
activity (B) but not DNA topoisomerase I activity (C) following covalent
photoincorporation of 8N3-ATP to wild type recombinant Topo I. (A) Increasing
the concentrations of either ATP (filled symbols) or 8N3-ATP (open symbols)
induced marked decrease of 25 and 27% respectively in the relative intrinsic
fluorescence of Topo I upon excitation at 295 nm. The relative Kd values
derived from the curves fitting are 55 nM for ATP and 65 nM for 8N3-ATP.
(B) Kinase assays were carried out with 100 ng of unirradiated (lane 1) or
irradiated Topo I in the absence (lane 2) or the presence of either 10 µM (lane 3)
or 100 µM (lane 4) of 8N3-ATP. (C, lanes 1–4) 20 ng of the same Topo I samples
as those corresponding to lanes 1–4 in (B) were incubated with 500 ng of
supercoiled DNA and assayed for DNA relaxation activity (Materials and
Methods). For kinase assays the 8N3-ATP cross-linked topo I/kinase was
diluted 10 times in buffer B, for relaxation assays it was diluted 50 times in
buffer B. (Pl) Supercoiled DNA incubated under the relaxation assay with
buffer only. CL stands for UV cross-linking.
of 8N3-ATP to purified recombinant DNA topoisomerase I
preparations induced a 27% reduction in quenching of the
intrinsic fluorescence (Fig. 2A) similar to that produced by ATP.
Such a large change in the protein fluorescence reveals that some
tryptophan residues are directly or indirectly involved in the
nucleotide binding. The curve fitting was consistent with the
possibility that DNA topoisomerase I has one 8N3-ATP binding
site. The estimated dissociation constant Kd of 65 nM for
8N3-ATP is similar to that previously observed for ATP,
indicating that 8N3-ATP binds with similar affinity as ATP to
isolated DNA topoisomerase I.
Another criterion for whether 8N3-ATP can bind to the ATP
site is the inhibition of the kinase reaction catalyzed by topo I/
kinase. UV irradiation of topo I/kinase in the presence of
8N3-ATP led to an irreversible loss of activity (Fig. 2B, lanes 3
and 4); ATP specifically protected topo I/kinase against this
inactivation (data not shown). The phosphorylation of SF2/ASF
was indeed reduced >20-fold when topo I/kinase and 8N3-ATP
were irradiated together and diluted in the kinase assay mixture
(Fig. 2B, compare lanes 2 and 4), whereas topo I/kinase and
8N3-ATP irradiated separately and then mixed to the same final
concentration had the same activity as unirradiated topo I/kinase
or enzyme irradiated in the absence of 8N3-ATP (Fig. 2B, lanes 1
and 2). No inhibition of the kinase activity was observed when
topo I/kinase and 8N3-ATP were mixed but not irradiated before
being diluted into the kinase assay mixture (data not shown). In
contrast, irradiated topo I/kinase was still capable of relaxing
supercoiled plasmid DNA as unirradiated topo I (Fig. 2C),
indicating that amino acids involved in the DNA catalyzed
reaction are different than those engaged in interactions with ATP.
Under the conditions we developed for photolabeling,
[α-32P]8N3-ATP binds covalently to topo I/kinase. To increase the
cross-linking efficiency, AMP-α-S (10 µM) was used because it
reduces non-specific cross-linking of 8N3-ATP without affecting the
phosphorylation of SF2/ASF (Fig. 3A) or the binding of ATP to topo
I/kinase (data not shown). Incorporation of the label increases
linearly for 1 min and reaches a maximum of ∼0.6 mol of 8N3-ATP
bound/mol of protein (Fig. 3B and C). No labeling occurred without
UV irradiation (Fig. 3B, lane 1) even after incubating for as long as
20 min. In addition, topo I/kinase that was heat denatured (by brief
incubation for 20 s in a 100C water bath), was not labeled,
demonstrating a requirement for native protein conformation for
labeling (data not shown). Autoradiography of SDS–polyacryla-
mide gel showed that the label was primarily incorporated into the
human DNA topoisomerase I protein band and two additional
bands with a molecular mass of 60 and 40 kDa were occasionally
observed after longer exposure to UV light (Fig. 3B). The latter
are proteolytic fragments which were generated following topo
I/kinase UV irradiation since they were absent from the
unirradiated sample (data not shown). These results indicate that
the dose of UV light used to cross-link 8N3-ATP to topo I/kinase
does not produce significant amounts of either intra- or interchain
cross-links which would alter protein mobility. Further proof of
this is that the fragments obtained by chymotrypsin digestion of
both unirradiated topo I/kinase and topo I/kinase exposed to UV
light, analyzed on SDS–polyacrylamide gels, were identical (Fig.
4, compare A and B left panel).
Previous studies have established that limited proteolysis of
DNA topoisomerase I under non-denaturing conditions yields
discrete polypeptides which appear to represent independently
folded structural domains (26). However, the spatial relationships
of the domains have not yet been elucidated. To localize the
8N3-ATP binding, photolabeled topo I/kinase was subjected to
proteolytic digestion and analyzed for stoichiometric label
incorporation using SDS–PAGE and autoradiography. The time
course for chymotrypsin proteolysis of topo I/kinase is shown in
Figure 4A and B. For convenience, we will refer to the various
proteolytic fragments according to their electrophoretic mobi-
lities relative to protein size markers. Two major fragments of ∼24
and 80K are produced at 5 min (lane 2), the earliest time
examined. These two fragments were HPLC purified and
subjected to N-terminal sequence analysis. The 24K fragment
proved to be the N-terminus of DNA topoisomerase I, while the
80K started with Lys 137. Given the unusual gel migration of the
first 175 amino acids of DNA topoisomerase I (26), the
NH2-terminal sequence information and the relative sizes of the
proteolytically released fragments, we propose that chymotrypsin
is cleaving predominantly after Leu 136. Given that chymotryp-
sin has specificity for cleaving on the C-terminal side of aromatic
residues and only has weak activity with hydrophobic, aliphatic
residues, the cleavage at Leu 136 is likely to reflect accessibility
of this region to proteases. Consistent with this interpretation, the
finding that NH2-terminal domain (Met 1–Lys 197) is highly
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Figure 3. Time course of cross-linking of [α32P]8N3-ATP to Topo I.
(A) Kinase reactions were performed as described (Materials and Methods)
without (lane Ctr) or with 1 µM (lane 2) 10 µM (lane 3) 100 µM (lane 4) and
1 mM (lane 5) of AMP-α-S, which act as protective compounds in the
photolabeling reaction. The photolabeled proteins were analyzed on a 12%
SDS–polyacrylamide gel and revealed either by autoradiography (B) or
quantitated by phosphor imaging (C). The position of the Topo I on the gel was
localized by staining the gel with Coomassie blue. (*) corresponds to Topo I
proteolytic fragments resulting from exposure of the protein to UV light.
A
B
C
sensitive to proteolysis (26), in particular, it has been shown that
the Arg 138 and Lys 175 were preferentially cleaved by an
unidentified insect cell protease.
[α-32P]8N3-ATP was cross-linked to each of the proteolytic
fragments, but the efficiency of cross-linking was different (Fig. 4B,
right panel). The N-terminal domain was labeled less extensively
(12–20% incorporation) compared with the 80K domain, which
showed 70–80% incorporation (lanes 2–6). Continued digestion
leads to the release of smaller labeled fragments with molecular
weight corresponding to 66, 22, 14 and 12K (derived from the 14K
fragment) (Fig. 4B, lanes 5 and 6 right panel). Those fragments are
also visible with Coomassie staining (Fig. 4B, left panel). The 22K
is the proteolytic product of the 24K peptide (Fig. 5A), since both
fragments are absent from the proteolysis pattern observed for 
topo I/kinase lacking the first 138 amino acids (Fig. 5A, Topo-80).
N-terminal sequencing of the 66 and 14K fragments provided
evidence that they are derived from the 80K fragment by
proteolysis at Glu 641. The 66K corresponds to the N-terminus
and the 14K corresponds to the C-terminus of the 80K fragment.
When the radioactivity incorporated into these two polypeptides
was compared with the total radioactivity in the 80K fragment, it
appeared that the C-terminal region was 2-fold more strongly
labeled than the N-terminal region. This is an estimation, given
that the C-terminal domain of human DNA topoisomerase I (total
Figure 4 . Limited chymotrypsin digestion of unirradiated (A) and irradiated
(B) Topo I. Digestion was performed at 30C with 0.1 % w/w chymotrypsin.
Samples (2 µg of protein) were removed at the indicated times and analyzed on
a 10–16% SDS–polyacrylamide gel. (A) Coomassie blue stained gel of
unirradiated sample (left panel) and schematic representation of Topo I
proteolytic fragments obtained by limited chymotrypsin digestion (right panel).
The arrows indicates the cleavage sites at lysine 137 and glutamic acid 641.
(B) Coomassie blue stained (left panel) and autoradiography (right panel) of the
gel corresponding to the irradiated sample. M, molecular weight. The relative
size of proteolytic fragments are indicated. (*) corresponds to Topo I proteolytic
fragments resulting from exposure of the protein to UV light. ChTy stands for
chymotrypsin.
A
B
Mr of 14 000) is split into small polypeptides even under
conditions of limited proteolysis (26) whereas the 66K represents
the core domain of the protein known to be resistant to
proteolysis. These findings indicate that there are two polypep-
tides that contain the bulk of the incorporated label which localize
to both the 24K N-terminal (136 amino acids) and 14K
C-terminal regions of topo I/kinase; this is consistent with
photolabeling at two specific sites in the protein but contrasts with
the early finding that topo I/kinase has only a single ATP binding
site.
Topo I/kinase regions might be cross-linked to 8N3-ATP either
at the ATP binding domain or at another site in the proximity of
this domain. A third possibility could be that the ATP binding
domain is formed by amino acids in the N-terminal and
C-terminal domains in the tertiary conformation of topo I/kinase.
We attempted to distinguish between these possibilities by making
deletions in the cDNA encoding human DNA topoisomerase I and
expressing the mutated proteins with the baculovirus system. We
first constructed a recombinant baculovirus encoding a 82K protein
(Topo-80) which lacks the first 138 amino acids of the N-terminal
domain of topo I/kinase corresponding to N-terminal 24K
domain, but contains 38 amino acids from the transfer vector.
These additional N-terminal amino acids include a six histidine
tag to allow efficient purification of the recombinant protein by
metal affinity chromatography. The recombinant protein purified
to apparent homogeneity (Fig. 5A, lane 5) displays kinase and
topoisomerase I activities equivalent to that of full-length DNA
topoisomerase I protein (Fig. 5C and D, compare lanes 1, 2 and
3, 4, respectively), indicating that the 24K domain is dispensable
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Figure 5. Comparison of chymotrypsin proteolytic patterns of photolabeled recombinant Topo I mutant proteins (A) and Kd determination of ATP binding to each
protein (B); protein kinase (C) and topoisomerase I (D) activities. (A) Coomassie blue staining of proteolytic digestion of full length, Topo-80 and Topo-δC (left panel),
autoradiography of photolabeled proteins digested with chymotrypsin (right panel). The incubation times are indicated on the top and the relative size of proteolytic
fragments are indicated on the left and right of each panel. (*) corresponds to proteolytic fragments resulting from exposure of recombinant proteins to UV light.
(B) Curves of intrinsic fluorescence quenching following binding of ATP to full length Topo I (filled circles), Topo-80 (open circles) and Topo-δC (triangle). The Kd
values derived from this analysis are indicated on the right of the panel. (C) Protein kinase assays were as described in Materials and Methods with 100 ng (lane 1),
or 10 ng (lane 2) of wild type Topo I; 100 ng (lane 3), or 10 ng (lane 4) of Topo-80; 100 ng (lane 5), or 10 ng (lane 6) of Topo-δC. (D) DNA topoisomerase I assays
were as described in Materials and Methods with 2 ng (lane 1), or 20 ng (lane 2) of wild type Topo I; 2 ng (lane 3), or 20 ng (lane 4) of Topo-80; 2 ng (lane 5), or
20 ng (lane 6) of Topo-δC. (Pl) Supercoiled DNA incubated under the relaxation assay in the presence of buffer.
A
B C D
for kinase activity. Moreover, this deletion did not greatly
interfere with the ability of Topo-80 to bind ATP, since the Kd for
ATP was <2-fold of that of the wild type (Fig. 5B). The 8N3-ATP
was incorporated in Topo-80 with the same efficiency as the full
length protein (Fig. 5A, right panel, compare lanes 1 and 5),
demonstrating that efficient crosslinking does not require an
intact N-terminal domain. Chymotryptic peptide mapping of
Topo-80 photolabeled with [α-32P]8N3-ATP revealed that labeling
was confined to the same fragments as those derived from the
80K domain of full length topo I/kinase (Fig. 5A, right panel,
compare lanes 2–4 and 6–8). Allowing for the absence of the 24K
domain, the digestion patterns of this protein and full length topo
I/kinase were very similar (Fig. 5A, left panel, compare lanes 2–4
and 6–8), generating two fragments of 66 and 14K with similar
kinetics. The slightly slower migration of 66K fragment derived
from Topo-80 (right panel, compare lanes 3, 4 and lanes 7, 8)
probably reflects the additional 38 amino acids that were inserted
during the construction of the expression vector. This was
confirmed by amino acid sequencing of the N-terminus (data not
shown). It is clear from these results that the N-terminal 24 kDa
fragment of topo I/kinase is not necessary for ATP binding and is
therefore not important for kinase activity.
We also examined the effect of deleting the C-terminal portion
of topo I/kinase on ATP binding and cross-linking to 8N3-ATP.
The recombinant fusion protein Topo-δC lacks the C-terminal
162 amino acids of human DNA topoisomerase I, but contains the
same N-terminal 38 amino acid tag as Topo-80. Although it has
the entire N-terminal amino acid sequence of the wild type topo I/
kinase, Topo-δC did not incorporate any label following UV
irradiation in the presence of [α-32P]8N3-ATP. Background labeling
of the mutant protein was negligible compared with wild type or
Topo-80 proteins (Fig. 5A, compare lanes 1–8 and lanes 9–12 in the
right panel). As shown in Figure 5B, millimolar levels of ATP did
not induce quantitative fluorescent quenching of Topo-δC, demon-
strating that deletion of the C-terminal domain leads to a mutated
protein with strongly impaired capacity to bind ATP. Thus the
requirement for ATP binding and 8N3-ATP cross-linking closely
paralleled one another. To rule out the trivial explanation that the lack
of ATP binding arises from an altered conformation for Topo-δC, we
tested its sensitivity to chymotrypsin digestion. Cleavage of
Topo-δC with chymotrypsin gave rise to two fragments correspon-
ding to 60 and 31K (Fig. 5A, left panel, lanes 9–12) as expected if
cleavage had occurred after Leu 136. The identity of these fragments
as the C- and N-terminal part of Topo-δC was confirmed by
sequencing the N-terminus of each fragment. Like the N-terminal
24K fragment of wild type Topo I, the 31K fragment migrated
aberrantly in the SDS–polyacrylamide gel because of the charged
residues in this region. Taken together, these results implicate the
C-terminal domain of DNA topoisomerase I in the binding of ATP.
The mutated protein was unable to phosphorylate SF2/ASF or to
relax supercoiled DNA (Fig. 5C and D, compare lanes 1, 2 and 5,
6, respectively), providing further evidence that the C-terminal
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Figure 6. Comparison of chymotrypsin proteolytic patterns of photolabeled wild type Topo I and Topo I (Y723F) recombinant proteins (A) and Kd determination of
ATP binding to each protein (B); protein kinase (C) and topoisomerase I (D) activities. (A) Coomassie blue staining of proteolytic digestion of equal amount of (Y723F)
Topo I and wild type Topo I (upper panel), autoradiography of photolabeled proteins digested with chymotrypsin (lower panel). The relative size of proteolytic
fragments are indicated on the left of each panel. (*) corresponds to proteolytic fragments resulting from exposure of recombinant proteins to UV light.
(B) Determination of the Kd of ATP binding to (Y723F) Topo I (closed circle) using the intrinsic fluorescence quenching of the protein and comparison with wild type
Topo I (open circles). The Kd values derived from this analysis are indicated on the right of the panel. (C) Protein kinase assays were as described in Materials and
Methods with 100 ng (lane 1), or 10 ng (lane 2) of wild type Topo I; 100 ng (lane 3), or 10 ng (lane 4) of (Y723F) Topo I. (D) DNA topoisomerase I assays were as
described in Materials and Methods with 2 ng (lane 1), or 20 ng (lane 2) of wild type Topo I; 2 ng (lane 3), or 20 ng (lane 4) of (Y723F)Topo I. (Pl) Supercoiled DNA
incubated under the relaxation assay in the presence of buffer.
domain of DNA topoisomerase I plays an essential role in reactions
catalyzed by this enzyme.
The C-terminal domain of DNA toipoisomerase I has also been
shown to catalyze the cleavage–ligation reactions characteristic of
Topo I (32). Since the experiments described above established that
the ATP binding site was contained in this domain, we decided to
determine whether the mechanism involved in transiently breaking
and resealing DNA strand is also involved in transferring the
phosphate from ATP to SF2/ASF. The tyrosine at position 723,
which serves to form a covalent bond with the 3′ phosphate of the
cleaved strand during the relaxation reaction, was mutated and its
effect on the ability of topo I/kinase to phosphorylate SF2/ASF was
examined. Figure 6A shows that substitution of tyrosine 723 by
phenylalanine did not change the proteolytic pattern of DNA
topoisomerase I when digested with chymotrypsin, confirming that
this mutation did not affect the conformation of the protein.
Furthermore, the mutated protein binds ATP with a Kd similar to
wild type (Fig. 6B) and efficiently incorporates 8N3-ATP at the
same region as wild type protein (Fig. 6A, lower panel, compare
lanes 1–4 and lanes 5–8). There was no quantitative difference in the
phosphorylation of SF2/ASF between wild type Topo I and the
mutant protein (Fig. 6C, compare lanes 1, 2 and 3, 4), confirming
that the tyrosine at the active site of DNA topoisomerase I is
dispensable for the kinase activity. In agreement with previous
observations, however, only trace amounts of insect cell-derived
topoisomerase I activity could be detected in the purified Y723F
Topo I even when assayed at very high protein concentration
(Fig. 6D, compare lanes 1, 2 and 3, 4). Therefore we conclude that
tyrosine 723 is not involved in the transfer of the γ-phosphate from
ATP to SF2/ASF, but is essential for DNA relaxation activity.
DISCUSSION
Limited proteolysis proved to be a useful tool for defining
structural domains whose boundaries closely parallel those
predicted from sequence comparisons of cellular Topo I enzymes
(26). The present study utilized this approach to define regions of
human DNA topoisomerase I contributing to the kinase activity.
Photoaffinity labeling with 8N3-ATP localized two regions
incorporating this ATP analog within the Topo I molecule. Two
observations confirm the significance of this labeling. The
reaction is efficient, since ∼50% of the input enzyme was
modified, and it is specific because ATP competed for the
photoinsertion of 8N3-ATP into the enzyme. Assuming that
8N3-ATP binds to topo I/kinase with similar affinity to ATP, and
that the covalent photoincorporation of 8N3-ATP into topo I/
kinase leads to its inactivation, it is reasonable to conclude that
8N3-ATP binds to the same site as ATP. Surprisingly, the sites
labeled with 8N3-ATP are within two distant regions of the
primary structure of topo I/kinase. One site localizes on the
N-terminal 24K domain and the other on the 14K C-terminal
domain. Nevertheless topo I/kinase has apparently only one ATP
binding site. Moreover, the native structure of topo I/kinase is
required for efficient photolabeling with 8N3-ATP, since heat
denaturation of the protein or deletion of the C-terminal region both
abolished cross-linking of 8N3-ATP. The mutant protein lacking the
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N-terminal 24K domain behaved as the full length topo I/kinase.
This deletion did not affect the Kd of the enzyme for ATP, its ability
to phosphorylate SF2/ASF, or the cross-linking efficiency to
8N3-ATP. Since we have established that the C-terminal domain
contributed to the ATP binding site, the crosslinking result suggest
that the N-terminal and C-terminal domains are closely situated in
the three dimensional structure of full length DNA topoisomerase I.
This conclusion is supported by the finding that SF2/ASF, the kinase
substrate, exclusively interacts with amino acids in the N-terminal
part of DNA topoisomerase I (Labourier et al., accompanying
paper). This interaction is essential for the phosphorylation of
SF2/ASF because a deletion mutation that impedes the binding of
SF2/ASF (Topo-70) also abolishes the kinase activity.
Further studies will be necessary to define the precise sequences
required for the topo I/kinase. Nevertheless the results presented here
imply that the C-terminal sequences are not obligatorily organized
in a structure identical to that required for DNA relaxation activity.
Site-directed mutagenesis of highly conserved amino acids at the
C-terminal domain of DNA topoisomerase I resulted in relaxation-
deficient mutants (32), demonstrating that the latter are involved in
cleavage–ligation reactions catalyzed by DNA topoisomerase I.
Substitution of tyrosine 723 in the active site (26,32,33), arginine
488 or lysine 532, lead to inactive DNA topoisomerase I; and
mutation of lysine 720 shows a 50-fold reduction in specific
relaxation activity (32). While ATP binds near tyrosine 723 at the
active site, mutation of this tyrosine did not affect either the binding
of ATP or the kinase activity of TopoI/kinase. This indicates that
tyrosine 723 is not involved in the transfer of the γ-phosphate from
ATP to SF2/ASF.
In addition, inclusion of ATP has no inhibitory effect in relaxation
reactions (34), however addition of DNA reduced the kinase activity
by at least 3-fold (9). This could be brought about by direct
competition between the two substrates for binding to the same site
and/or by changes in the conformation of the protein concerned to
bind ATP. The chymotryptic digestion profile of topo I/kinase was
the same in the presence or absence of ATP (data not shown), while
the binding of DNA to Topo I resulted in differential protease
sensitivity (26). Indeed, it was previously shown that noncovalent
binding of Topo I to plasmid DNA decreases the proteolysis of a
linker region (amino acids 652–696) situated between the core
domain (amino acids 175–659) and the C-terminal domain (26,33).
In contrast, covalent binding of a DNA oligonucleotide to the
C-terminal domain did not change the sensitivity of DNA
topoisomerase I to proteolysis. Since the conserved core domain
alone exhibits preferential binding to superhelical as compared with
relaxed DNA (33) and as the C-terminal domain contributes to the
binding of ATP, then this may account for changes in the
conformation of the C-terminal region during the DNA catalyzed
reaction, which would interfere with the binding of ATP thereby
impeding the kinase activity.
Understanding how the protein kinase and DNA relaxing
activities mediated by the same polypeptide are mechanistically
related and determining the way by which the splicing activity of SR
proteins is modulated by phosphorylation, will provide us with new
insights into functions of this enzyme. Clearly, X-ray crystallo-
graphy is needed to complete the biochemical characterization of
eukaryotic DNA topoisomerase I. Future work must, in addition,
concentrate on attempts to integrate our knowledge regarding
pathways by which SR proteins regulate splicing with studies of
topo I/kinase-mediated phosphorylation of SR proteins themselves.
Failure to properly phosphorylate SR proteins may perhaps account
for the lethality of the DNA topoisomerase I mutations in
Drosophila and mouse, and it will be interesting to dissect the DNA
relaxing and kinase activities of this molecule in both organisms.
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